Like and comment_老虎社区_美港股上老虎

2021-07-16

Like and comment

Why Moderna Stock Is Hitting Another Record High Today<blockquote>为什么Moderna股票今天再创历史新高</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":170032707,"tweetId":"170032707","gmtCreate":1626395019509,"gmtModify":1631893330298,"author":{"id":3572078772819787,"idStr":"3572078772819787","authorId":3572078772819787,"authorIdStr":"3572078772819787","name":"Winstonlou","avatar":"https://static.tigerbbs.com/872d534505dadd9f2bcdebec4b5df367","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Like and comment</body></html>","htmlText":"<html><head></head><body>Like and comment</body></html>","text":"Like and comment","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/170032707","repostId":1140595356,"repostType":4,"repost":{"id":"1140595356","kind":"news","pubTimestamp":1626387586,"share":"https://www.laohu8.com/m/news/1140595356?lang=zh_CN&edition=full","pubTime":"2021-07-16 06:19","market":"us","language":"en","title":"Why Moderna Stock Is Hitting Another Record High Today<blockquote>为什么Moderna股票今天再创历史新高</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1140595356","media":"Motley Fool","summary":"The vaccine stock benefited from two positive developments.\n\nKey Points\n\nA Wall Street analyst raise","content":" The vaccine stock benefited from two positive developments. Key Points<blockquote>疫苗股受益于两个积极的发展。要点</blockquote> <ul> <li>A Wall Street analyst raised his price target for Moderna.</li> <li>A top European official also stated that a recommendation on authorization for Moderna's COVID-19 vaccine would probably be made by late next week.</li> </ul> What happened<blockquote><ul><li>一位华尔街分析师上调了Moderna的目标价。</li><li>一名欧洲高级官员还表示，可能会在下周晚些时候提出授权Moderna新冠肺炎疫苗的建议。</li></ul>发生了什么</blockquote> Shares ofModerna(NASDAQ:MRNA)were jumping 4.3% as of 11:10 a.m. EDT on Thursday, hitting another record high for the stock. The bump came after Michael Yee, an analyst atJefferies, increased his price target on the stock from $170 to $250.<blockquote>本公司之股份现代截至美国东部时间周四上午11点10分，（纳斯达克：MRNA）股价上涨4.3%，再创历史新高。这一上涨是在分析师Michael Yee之后发生的杰弗里斯，将该股目标价从170美元上调至250美元。</blockquote> Also, Dr. Marco Cavaleri, the European Medicines Agency (EMA) head of biological health threats and vaccines strategy, stated in a press conference that a committee would likely finalize a decision on recommending authorization for Moderna's COVID-19 vaccine in children by the end of next week.<blockquote>此外，欧洲药品管理局（EMA）生物健康威胁和疫苗战略负责人Marco Cavaleri博士在新闻发布会上表示，一个委员会可能会在年底前最终决定建议授权Moderna的COVID-19疫苗用于儿童。下周。</blockquote> So what<blockquote>那又怎样</blockquote> Jefferies' higher price target for thevaccine stockreflected expectations of increased sales for Moderna's COVID-19 vaccine this year. Yee now looks for the company to up its full-year revenue guidance to $21 billion. It previously projected sales of $19.2 billion.<blockquote>杰富瑞(Jefferies)对疫苗股的较高目标价反映了对Moderna的COVID-19疫苗今年销量增加的预期。Yee现在希望该公司将全年收入指引提高至210亿美元。该公司此前预计销售额为192亿美元。</blockquote> The EMA's decision on authorization of the vaccine in immunizing children ages 12 to 17 could play a key role in driving higher sales. Although there are many more adults in the European Union than children, the pediatric market presents a big opportunity for the company.<blockquote>EMA关于授权该疫苗用于12至17岁儿童免疫的决定可能会在推动更高的销售额方面发挥关键作用。尽管欧盟的成年人比儿童多得多，但儿科市场为该公司提供了一个巨大的机会。</blockquote> Neither of these news items, however, were compelling reasons for Moderna's shares to move higher. Jefferies' price target is actually lower than its current share price. Also, Cavaleri's comments about the pending decision by an expert committee didn't provide any hints as to what the recommendation would be.<blockquote>然而，这两条新闻都不是Moderna股价走高的令人信服的理由。杰富瑞的目标价实际上低于其当前股价。此外，卡瓦莱里对专家委员会悬而未决的决定的评论没有提供任何关于建议是什么的暗示。</blockquote> Now what<blockquote>现在怎么办</blockquote> The most important thing to watch with Moderna in the near term isn't the EMA committee announcement next week. Instead, it's the company's second-quarter update scheduled for Aug. 5. Moderna is likely to boost its full-year sales outlook in that update.<blockquote>Moderna近期最值得关注的不是EMA委员会下周的公告。相反，这是该公司定于8月5日发布的第二季度更新。Moderna可能会在此次更新中提高其全年销售前景。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Is Hitting Another Record High Today<blockquote>为什么Moderna股票今天再创历史新高</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Is Hitting Another Record High Today<blockquote>为什么Moderna股票今天再创历史新高</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-16 06:19\n\n</h4>\n</header>\n<article>\n The vaccine stock benefited from two positive developments. Key Points<blockquote>疫苗股受益于两个积极的发展。要点</blockquote> <ul> <li>A Wall Street analyst raised his price target for Moderna.</li> <li>A top European official also stated that a recommendation on authorization for Moderna's COVID-19 vaccine would probably be made by late next week.</li> </ul> What happened<blockquote><ul><li>一位华尔街分析师上调了Moderna的目标价。</li><li>一名欧洲高级官员还表示，可能会在下周晚些时候提出授权Moderna新冠肺炎疫苗的建议。</li></ul>发生了什么</blockquote> Shares ofModerna(NASDAQ:MRNA)were jumping 4.3% as of 11:10 a.m. EDT on Thursday, hitting another record high for the stock. The bump came after Michael Yee, an analyst atJefferies, increased his price target on the stock from $170 to $250.<blockquote>本公司之股份现代截至美国东部时间周四上午11点10分，（纳斯达克：MRNA）股价上涨4.3%，再创历史新高。这一上涨是在分析师Michael Yee之后发生的杰弗里斯，将该股目标价从170美元上调至250美元。</blockquote> Also, Dr. Marco Cavaleri, the European Medicines Agency (EMA) head of biological health threats and vaccines strategy, stated in a press conference that a committee would likely finalize a decision on recommending authorization for Moderna's COVID-19 vaccine in children by the end of next week.<blockquote>此外，欧洲药品管理局（EMA）生物健康威胁和疫苗战略负责人Marco Cavaleri博士在新闻发布会上表示，一个委员会可能会在年底前最终决定建议授权Moderna的COVID-19疫苗用于儿童。下周。</blockquote> So what<blockquote>那又怎样</blockquote> Jefferies' higher price target for thevaccine stockreflected expectations of increased sales for Moderna's COVID-19 vaccine this year. Yee now looks for the company to up its full-year revenue guidance to $21 billion. It previously projected sales of $19.2 billion.<blockquote>杰富瑞(Jefferies)对疫苗股的较高目标价反映了对Moderna的COVID-19疫苗今年销量增加的预期。Yee现在希望该公司将全年收入指引提高至210亿美元。该公司此前预计销售额为192亿美元。</blockquote> The EMA's decision on authorization of the vaccine in immunizing children ages 12 to 17 could play a key role in driving higher sales. Although there are many more adults in the European Union than children, the pediatric market presents a big opportunity for the company.<blockquote>EMA关于授权该疫苗用于12至17岁儿童免疫的决定可能会在推动更高的销售额方面发挥关键作用。尽管欧盟的成年人比儿童多得多，但儿科市场为该公司提供了一个巨大的机会。</blockquote> Neither of these news items, however, were compelling reasons for Moderna's shares to move higher. Jefferies' price target is actually lower than its current share price. Also, Cavaleri's comments about the pending decision by an expert committee didn't provide any hints as to what the recommendation would be.<blockquote>然而，这两条新闻都不是Moderna股价走高的令人信服的理由。杰富瑞的目标价实际上低于其当前股价。此外，卡瓦莱里对专家委员会悬而未决的决定的评论没有提供任何关于建议是什么的暗示。</blockquote> Now what<blockquote>现在怎么办</blockquote> The most important thing to watch with Moderna in the near term isn't the EMA committee announcement next week. Instead, it's the company's second-quarter update scheduled for Aug. 5. Moderna is likely to boost its full-year sales outlook in that update.<blockquote>Moderna近期最值得关注的不是EMA委员会下周的公告。相反，这是该公司定于8月5日发布的第二季度更新。Moderna可能会在此次更新中提高其全年销售前景。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/15/why-moderna-stock-is-hitting-another-record-high-t/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/07/15/why-moderna-stock-is-hitting-another-record-high-t/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140595356","content_text":"The vaccine stock benefited from two positive developments.\n\nKey Points\n\nA Wall Street analyst raised his price target for Moderna.\nA top European official also stated that a recommendation on authorization for Moderna's COVID-19 vaccine would probably be made by late next week.\n\nWhat happened\nShares ofModerna(NASDAQ:MRNA)were jumping 4.3% as of 11:10 a.m. EDT on Thursday, hitting another record high for the stock. The bump came after Michael Yee, an analyst atJefferies, increased his price target on the stock from $170 to $250.\nAlso, Dr. Marco Cavaleri, the European Medicines Agency (EMA) head of biological health threats and vaccines strategy, stated in a press conference that a committee would likely finalize a decision on recommending authorization for Moderna's COVID-19 vaccine in children by the end of next week.\nSo what\nJefferies' higher price target for thevaccine stockreflected expectations of increased sales for Moderna's COVID-19 vaccine this year. Yee now looks for the company to up its full-year revenue guidance to $21 billion. It previously projected sales of $19.2 billion.\nThe EMA's decision on authorization of the vaccine in immunizing children ages 12 to 17 could play a key role in driving higher sales. Although there are many more adults in the European Union than children, the pediatric market presents a big opportunity for the company.\nNeither of these news items, however, were compelling reasons for Moderna's shares to move higher. Jefferies' price target is actually lower than its current share price. Also, Cavaleri's comments about the pending decision by an expert committee didn't provide any hints as to what the recommendation would be.\nNow what\nThe most important thing to watch with Moderna in the near term isn't the EMA committee announcement next week. Instead, it's the company's second-quarter update scheduled for Aug. 5. Moderna is likely to boost its full-year sales outlook in that update.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":302,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":14,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/170032707"}